NB004 / Ningbo Tai Kang - LARVOL DELTA

Preclinical antitumor activity and first-in-human phase I study of NB004/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors (AACR 2024) - P1 | "Remarkably, in NSCLC PDX models with acquired resistance to KRASis, strong combination efficacy was observed between NB004 and sotorasib, resulting in complete tumor regression. These results warrant further evaluation of this drug in combination with other therapeutic agents. The combination part of the trial is currently open for enrollment (NCT05036291)."

Metastases • P1 data • Preclinical • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • PIM1

Lead Optimization Yielding a pan-Pim Inhibitor GDC-0570/NB004 for Cancer Treatment in the Clinical Testing (ACS-Sp 2024) - "The structure of GDC-0570 has not been disclosed. Currently, GDC-0570 is in active Phase 1 clinical trial."

Clinical • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: Ningbo Newbay Technology Development Co., Ltd | N=36 ➔ 120 | Trial completion date: Sep 2023 ➔ Jun 2025 | Trial primary completion date: May 2023 ➔ Feb 2025

Combination therapy • Enrollment change • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Discovery of GDC-0570/NB004 as a second-generation pan-Pim inhibitor through extensive optimization for cancer treatment (ACS-Fall 2023) - "This is the first time that the structure of GDC-0570 will be fully disclosed. Currently, GDC-0570 is in active phase 1 clinical trial."

Hematological Malignancies • Multiple Myeloma • Oncology